U.S. markets close in 4 hours 47 minutes
  • S&P 500

    3,773.36
    -45.47 (-1.19%)
     
  • Dow 30

    30,683.34
    -345.97 (-1.11%)
     
  • Nasdaq

    10,995.81
    -182.08 (-1.63%)
     
  • Russell 2000

    1,695.44
    -23.93 (-1.39%)
     
  • Crude Oil

    105.65
    -4.13 (-3.76%)
     
  • Gold

    1,808.40
    -9.10 (-0.50%)
     
  • Silver

    20.18
    -0.56 (-2.69%)
     
  • EUR/USD

    1.0454
    +0.0010 (+0.09%)
     
  • 10-Yr Bond

    3.0110
    -0.0820 (-2.65%)
     
  • GBP/USD

    1.2148
    +0.0026 (+0.22%)
     
  • USD/JPY

    135.8620
    -0.6830 (-0.50%)
     
  • BTC-USD

    19,132.32
    -966.92 (-4.81%)
     
  • CMC Crypto 200

    409.69
    -21.77 (-5.05%)
     
  • FTSE 100

    7,156.82
    -155.50 (-2.13%)
     
  • Nikkei 225

    26,393.04
    -411.56 (-1.54%)
     

See Why Alzamend Neuro Stock Is Rallying On Thursday

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Alzamend Neuro Inc (NASDAQ: ALZN) has received a written response to its meeting request regarding the FDA's Type B Pre‑Investigational New Drug (Pre-IND) application.

  • Today's response provides a path for its planned clinical development of AL002, the Company says.

  • AL002 uses a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.

  • The FDA agreed to Alzamend's proposed combined Phase 1/2 study.

  • Alzamend will file the IND by the end of November and initiate the clinical trial of AL002 in Q1 of 2022.

  • Related: Alzamend Recruits Altasciences To Conduct Early-Stage Trial Of Its Alzheimer's Candidate.

  • Price Action: ALZN stock increased 33.5% at $3.04 during the market session on the last check Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.